Dr-COVID: Graph Neural Networks for SARS-CoV-2 Drug Repurposing

• URL: http://arxiv.org/abs/2012.02151v1
• Date: Thu, 3 Dec 2020 18:34:10 GMT
• Title: Dr-COVID: Graph Neural Networks for SARS-CoV-2 Drug Repurposing
• Authors: Siddhant Doshi and Sundeep Prabhakar Chepuri
• Abstract summary: We propose a dedicated graph neural network (GNN) based drug repurposing model, called Dr-COVID. Dr-COVID is evaluated in terms of its prediction performance and its ability to rank the known treatment drugs for diseases as high as possible.
• Score: 14.112444998191698
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: The 2019 novel coronavirus (SARS-CoV-2) pandemic has resulted in more than a million deaths, high morbidities, and economic distress worldwide. There is an urgent need to identify medications that would treat and prevent novel diseases like the 2019 coronavirus disease (COVID-19). Drug repurposing is a promising strategy to discover new medical indications of the existing approved drugs due to several advantages in terms of the costs, safety factors, and quick results compared to new drug design and discovery. In this work, we explore computational data-driven methods for drug repurposing and propose a dedicated graph neural network (GNN) based drug repurposing model, called Dr-COVID. Although we analyze the predicted drugs in detail for COVID-19, the model is generic and can be used for any novel diseases. We construct a four-layered heterogeneous graph to model the complex interactions between drugs, diseases, genes, and anatomies. We pose drug repurposing as a link prediction problem. Specifically, we design an encoder based on the scalable inceptive graph neural network (SIGN) to generate embeddings for all the nodes in the four-layered graph and propose a quadratic norm scorer as a decoder to predict treatment for a disease. We provide a detailed analysis of the 150 potential drugs (such as Dexamethasone, Ivermectin) predicted by Dr-COVID for COVID-19 from different pharmacological classes (e.g., corticosteroids, antivirals, antiparasitic). Out of these 150 drugs, 46 drugs are currently in clinical trials. Dr-COVID is evaluated in terms of its prediction performance and its ability to rank the known treatment drugs for diseases as high as possible. For a majority of the diseases, Dr-COVID ranks the actual treatment drug in the top 15.

Related papers

• Emerging Drug Interaction Prediction Enabled by Flow-based Graph Neural Network with Biomedical Network [69.16939798838159]
  We propose EmerGNN, a graph neural network (GNN) that can effectively predict interactions for emerging drugs. EmerGNN learns pairwise representations of drugs by extracting the paths between drug pairs, propagating information from one drug to the other, and incorporating the relevant biomedical concepts on the paths. Overall, EmerGNN has higher accuracy than existing approaches in predicting interactions for emerging drugs and can identify the most relevant information on the biomedical network.
  arXiv  Detail & Related papers  (2023-11-15T06:34:00Z)
• NeuroCADR: Drug Repurposing to Reveal Novel Anti-Epileptic Drug Candidates Through an Integrated Computational Approach [0.0]
  Drug repurposing is an emerging approach for drug discovery involving the reassignment of existing drugs for novel purposes. A proposed algorithm is NeuroCADR, a novel system for drug repurposing via a multi-pronged approach consisting of k-nearest neighbor algorithms (KNN), random forest classification, and decision trees. Data was sourced from several databases consisting of interactions between diseases, symptoms, genes, and affiliated drug molecules, which were then compiled into datasets expressed in binary. NeuroCADR identified novel drug candidates for epilepsy that can be further approved through clinical trials.
  arXiv  Detail & Related papers  (2023-09-04T03:21:43Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Knowledge-Driven New Drug Recommendation [88.35607943144261]
  We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs. EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base. Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
  arXiv  Detail & Related papers  (2022-10-11T16:07:52Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• Genetic Constrained Graph Variational Autoencoder for COVID-19 Drug Discovery [0.0]
  We propose a new model called Genetic Constrained Graph Variational Autoencoder (GCGVAE) to solve this problem. We trained our model based on the data of various viruses' protein structure, including that of the SARS, HIV, Hep3, and MERS, and used it to generate possible drugs for SARS-CoV-2. Our generated molecules have great effectiveness in inhibiting SARS-CoV-2.
  arXiv  Detail & Related papers  (2021-04-23T16:10:15Z)
• Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence [9.472330151855111]
  We built a SARS-CoV-2 knowledge graph based on the interactions among virus baits, host genes, pathways, drugs, and phenotypes. We prioritized the candidate drugs using clinical trial history, and then validated them with their genetic profiles, in vitro experimental efficacy, and electronic health records.
  arXiv  Detail & Related papers  (2020-09-23T04:47:59Z)
• CovidDeep: SARS-CoV-2/COVID-19 Test Based on Wearable Medical Sensors and Efficient Neural Networks [51.589769497681175]
  The novel coronavirus (SARS-CoV-2) has led to a pandemic. The current testing regime based on Reverse Transcription-Polymerase Chain Reaction for SARS-CoV-2 has been unable to keep up with testing demands. We propose a framework called CovidDeep that combines efficient DNNs with commercially available WMSs for pervasive testing of the virus.
  arXiv  Detail & Related papers  (2020-07-20T21:47:28Z)
• Repurpose Open Data to Discover Therapeutics for COVID-19 using Deep Learning [22.01390057543923]
  There have been more than 850,000 confirmed cases and over 48,000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic. There are currently no proven effective medications against COVID-19. This study reports an integrative, network-based deep learning methodology to identify repurposable drugs for COVID-19.
  arXiv  Detail & Related papers  (2020-05-21T16:02:29Z)
• Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19 [6.7410870290301]
  The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. Here, we deploy algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. We find that while most algorithms offer predictive power for these ground truth data, no single method offers consistently reliable outcomes across all datasets and metrics.
  arXiv  Detail & Related papers  (2020-04-15T17:40:29Z)
• Mapping the Landscape of Artificial Intelligence Applications against COVID-19 [59.30734371401316]
  COVID-19, the disease caused by the SARS-CoV-2 virus, has been declared a pandemic by the World Health Organization. We present an overview of recent studies using Machine Learning and, more broadly, Artificial Intelligence to tackle many aspects of the COVID-19 crisis.
  arXiv  Detail & Related papers  (2020-03-25T12:30:33Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.